echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Drug-based NoriKirensai injections are to be prioritized for new adaptations to be ground-breaking therapies!

    Drug-based NoriKirensai injections are to be prioritized for new adaptations to be ground-breaking therapies!

    • Last Update: 2020-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The drug, which filed for listing on June 30, is the second CAR-T therapy in the country to do so.
    Ricky Lunsai Injection (tentative) (developed code: JWCAR029) is a CAR-T product developed by ThermoJono on the basis of JCAR017 in the United States, which was submitted to IND in December 2017 through Ming Polyseth for a clinical study on the treatment of relapsed lymphoma and leukemia, which was accepted in January 2018.
    Insight database shows that the fastest-growing clinical treatment of recurring refractic B-cell non-Hodgkin's lymphoma is currently the fastest-growing clinical in China, and it is expected that the indications listed this time will be relapsed refractic B-cell non-Hodgkin's lymphoma.
    addition, JWCAR029 for the treatment of primary drug resistance diffuse large B cell lymphoma is also in clinical phase 1, it is assumed that the adaptive disorder is intended to be included in the breakthrough therapy of the adaptation.
    Photo Source: Insight Database () Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development, transformation and promotion of leading cellular immunotherapy, was founded in April 2016.
    completed a $100 million round of Round B financing on June 9 this year, plus a total of more than $200 million raised.
    is the first company in China to obtain IND clinical approvals for CAR-T cell (embedded antigen-treated T-cell) therapeutic products with CD19 as its target, leading THE CAR-T clinical research in China.
    But on February 24, 2020, Fosun Kate's inlay antigen-treated T-cell (CAR-T) therapy Ikililunsai injection, introduced from Kite, was the first to submit a listing application, temporarily ahead of the drug Ming Juno.
    at the 2019 ASH Conference, Drug Minerno announced the clinical efficacy of JWCAR029 for the treatment of R/R B-NHL.
    study showed that for patients with poor prognostic R/R invasive B-NHL, infusion JWCAR029 provided good and lasting remission, with an ORR of 58.6% for all patients at 6 months, a CR rate of 55.2% ;D and an ORR of 45% for LBCL patients and a CR rate of 45%.
    safety, JWCAR029-related adverse events are controllable, there are no CRS or NT-related deaths, and the 3/4 crS or NT rate is low, at approximately 6%.
    two CAR-T products are currently on the market worldwide, both targeting CD19, Novart's Kymriah and Gilead's Kite's Yescarta.
    The former is approved for second-line or above treatment in patients under 25 years of age with relapsed difficult-to-treat B-cell acute lymphoblastic leukemia (B-ALL) and adult patients with DLBCL, and the latter is approved for second-line treatment in two non-Hodgkin's lymphoma NHL, including DLBCL and the more rare primary diaphragm large B-cell lymphoma (PMBCL) adult patients.
    , Yescarta has outperformed both CAR-T products in terms of post-market sales, with sales of $456 million in 2019, up 72.7% year-on-year.
    's Kymriah has sales of $278 million in 2019.
    yescarta's listing in China has helped to increase its competitiveness.
    Table 1 Domestic and Foreign Target CD19 CAR-T Major Registered Clinical Trial Progress Statistical Date Ended: July 1 Original Title: Pharmaceutical Ming Juno CAR-T Product "Ricky Lunsey Injection" to be reviewed as a priority, new adaptations to breakthrough therapy!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.